Found: 5
Select item for more details and to access through your institution.
Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration.
- Published in:
- Cancer Medicine, 2024, v. 13, n. 17, p. 1, doi. 10.1002/cam4.70138
- By:
- Publication type:
- Article
Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial.
- Published in:
- Cancer Medicine, 2019, v. 8, n. 4, p. 1401, doi. 10.1002/cam4.1980
- By:
- Publication type:
- Article
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 2, p. e40, doi. 10.1016/j.clml.2023.10.003
- By:
- Publication type:
- Article
Single Institution Experience with Nivolumab in Treatment of Patients with Relapsed or Refractory Hodgkin’s Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S323, doi. 10.1016/j.clml.2017.07.131
- By:
- Publication type:
- Article
Real-world effectiveness and safety of daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma in Slovakia.
- Published in:
- Neoplasma, 2021, v. 68, n. 3, p. 626, doi. 10.4149/neo_2021_201113N1223
- By:
- Publication type:
- Article